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perfusion during cardiopulmonary bypass in patients with
severe atherosclerotic or aneurysmal disease.-+ From our
experience, we believe cannulation of the left subclavian
artery through a prosthetic graft to be a safe, easy, and effec-
tive way of arterial cannulation for cardiopulmonary bypass
in patients undergoing hypothermic repair of thoracic or tho-
racoabdominal aneurysms. In addition, a prosthetic graft used
for arterial perfusion is also available for later reconstruction
of the left subclavian artery system when necessary.
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The sympathetic denervation induced by transmyo-
cardial laser revascularization protects the affected
tissue
To the Editor:
Having a strong interest in the mechanism of transmyocar-
dial laser revascularization (TLR),I I appreciated the article
by Kwong and associates2 about the sympathetic denervation
of canine myocardium induced by TLR. The authors believe
that such denervation contributes to the angina relief
observed in clinical situations. Their results (the absence of
tyrosine hydroxylase in the denervated myocardium) also
suggest, however, that the denervation blocks not only affer-
ent nociceptive stimuli but also possible efferent sympathetic
overstimulation. This hypothesis is supported by the follow-
ing facts: (1) efferent cardiac sympathetic tone and Circulat-
ing catecholamines are elevated in advanced heart failure3;
(2) increased efferent cardiac sympathetic tone and circulat-
ing catecholamines induce arrhythmias,3 dysfunctional
myocardial contractions,3 contraction band necrosis,-+ and
infarct-like myocardiallesions5; and (3) these functional dis-
turbances and lesions are often present in end-stage heart dis-
ease.3A In this situation, the sympathetic denervation induced
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by TLR, being able to abrogate injurious increased intramy-
ocardial catecholamine release, provides a partial protection
for the denervated myocardium.
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Cytokines and myocardial injury: Is there a scope
for magic bullets?
To the Editor:
In recent issues of the JournaL two studies suggested that
cytokines such as interleukin-6 OL-6)1 and IL-82 playa piv-
otal role in inducing myocardial ischemia-reperfusion injury.
Inasmuch as both cytokines are released during and after car-
diopulmonary bypass (CPB),3 the question was raised as to
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Fig 1. Possible mechanisms involved in myocardial injury
after CPB. PMN, Polymorphonuclear leukocytes. (Modified
from Wan S, LeClerc JL, Vincent JL. Inflammatory Response
to Cardiopulmonary Bypass: Mechanisms Involved and
Possible Therapeutic Strategies. Chest 1997;112:676-92.)
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whether neutralizing IL-6 or IL-8 before reperfuslOn could
result in improved myocardial preservatIOn.
Many factors have been causally hnked to myocardial
ischemia-reperfusion injury after CPB (Fig I). In fact. three
considerations suggest that IL-6 is unlikely to be a potent
mediator inducmg myocardial injury: (I) IL-6 has been
shown to be a marker rather than a critical mediator of
injury'; (2) IL-6 may have anti-inflammatory etlects through
direct suppression as well as the induction of the natural
antagonist of tumor necrosis factor-a.,.) which is also in-
volved in inducing myocardial dysfunction3; (3) even though
similar IL-6 production was noted in patients undergoing
coronary artery bypass grafting (CABG) through median
sternotomy with or without the use of CPB,5.6 a significantly
lower release of cardiac troponin-I was observed in the off-
pump group.6 These findings indicate IL-6 production
may be mfluenced by the degree of surgical trauma (ie,
surgical incision), without further inducing myocardial
injury.
Sawa and colleagues! reported that FUT-175. a serine
protease inhibitor, could suppress IL-6 production. It is pos-
sible, however, that FUT-175 does not inhibit the release of
IL-6, but merely delays this process. Only two samples were
taken in their study, before ischemia and 10 minutes after
reperfusion. I The peak release of IL-6, however, occurs at
least 2 hours later, simply because it is not a '"washout'"
phenomenon. 7
For its part, IL-8 is a crucial chemokine known to attract
and activate neutrophils as well as T lymphocytes and to con-
trol their trafficking. Clinical investigations have documented
that the myocardium is a major source of IL-8 during reper-
fusion after longer durations of ischemia or after acute
myocardial infarction.3Inasmuch as neutrophil activation is a
critical early step in ischemia-reperfusion injury. it is certainly
not surprising to learn that administration of anti-IL-8 anti-
bodies prevents cardiopulmonary injury.2.8 Indeed, we" have
recently observed a strong correlation between IL-8 produc-
tion and postoperative cardiac troponin-I levels in patients
undergoing CABG. Although we agree with Boyle and col-
leagues" about the important role of IL-8. we believe that
there is no substantial evidence so far for any relevant medi-
ator to be the '"lethal activator."
Before trying to modulate an essentially biologiC functIOn
(ie, inflammation) with multiple antibodies (eg, anti-IL-6,
anti-IL-8, anti-intercellular adhesion molecule-I, anti-
CD 18) as proposed by Sawa and colieagues,l we should also
recognize that the balance among many interactive mediators.
together with their natural antagonists/antibodies or endoge-
nous soluble receptors, may be much more crucial. For
instance, the release of a key anti-inflammatory cytokine IL-
10, which is known to inhibit the productIOn of promflamma-
tory cytokines, is almost proportional to the release of IL-8
during clinical CPB,3 as well as in patients undergoing off-
pump CABG.6
We are just starting to understand the complexities of the
network. We should always make sure to aim our gun at the
right target before opening fire. The continued explosion in
molecular biologic knowledge will help to develop an ideal
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magic bullet or combinations of bullets to modulate rather
than to block an excessive inflammatory response.
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The "sternum calvary"
To the Editor:
We read with great interest the article by Tam, Garlick, and
Almeida! in the October 1997 issue of the Journal and the
related correspondence by Morishita, Kuwaky, Sato, and
Abe.2 The discussion concerns an elegant approach to many
valve operations through a less invasive sternotomy.
We have ditlerent comments related to this approach.
Although minimally invasive direct coronary artery bypass
(MIDCAB) procedures. avoiding cardiopulmonary bypass
(CPB) and cardiopleglc arrest, are truly minimally invasive,
in the field of valve surgery, debates continue over what con-
stitutes "Ie,s invasive" and which incision provides the best
exposure and sufficient space to mampulate the heart. Over
the past 2 years less mvasive approaches to valve surgery
have shown a tendency to switch from paramedian thoraco-
tomy to partial sternotomy. Table I lists different approaches
of partial sternotomy reported in the recent literature.
